source
- Definium's oral LSD candidate passes first Phase 3 trial in generalized anxiety disorderDefinium Therapeutics announced that its oral LSD candidate has successfully completed a Phase 3 trial in generalized anxiety disorder. The study met its primary endpoints, marking the first of tw…
- Boulevard Bio raises $65M to expand immunology pipeline, eyes Vera's IgAN candidateBoulevard Bio announced it has secured $65 million in financing to broaden its immunology portfolio. The new capital will support the development of two immune‑resetting drugs the company discovere…